🔬 Cell Signalling — Receptor Cascade & Signal Amplification
Model a G-protein coupled receptor (GPCR) signalling cascade: ligand binds receptor → receptor occupancy → G-protein activation → adenylyl cyclase → cAMP production → PKA phosphorylation. Explore signal amplification, adaptation, and Hill-function ultrasensitivity.
Biology / Physics
Receptor occupancy: [RL]/[RT] = [L]n/(KDn + [L]n) — the Hill equation. When n > 1 the response is switch-like (ultrasensitive). G-protein activation follows receptor occupancy. cAMP is produced by adenylyl cyclase (proportional to active G-proteins) and degraded by phosphodiesterase (PDE). PKA is activated by cAMP following another Hill function. Signal amplification: a single ligand-bound receptor can activate hundreds of G-proteins, each stimulating production of thousands of cAMP molecules, each activating many PKA enzymes — cascade amplification of ~10,000-fold.
About Cell Signalling — Receptor Cascade & Signal Amplification
This simulation models a G-protein coupled receptor (GPCR) signalling cascade, one of the most common signal transduction pathways in eukaryotic cells. A ligand (such as adrenaline or glucagon) binds to a surface receptor, triggering a chain of molecular events: G-protein activation, adenylyl cyclase stimulation, cAMP second messenger production, and finally PKA (protein kinase A) phosphorylation of target proteins. Users can adjust ligand concentration, receptor affinity (KD), Hill coefficient (cooperativity), and phosphodiesterase (PDE) activity to observe how each parameter shapes receptor occupancy, cAMP levels, PKA activation, and overall signal amplification in real time.
GPCR signalling governs responses to hormones, neurotransmitters, and sensory stimuli throughout the body — from the fight-or-flight adrenaline response to light detection in retinal photoreceptors. Understanding these cascades is central to pharmacology, since roughly 35% of all approved drugs target GPCRs.
Frequently Asked Questions
What is a GPCR signalling cascade?
A G-protein coupled receptor (GPCR) cascade is a multi-step amplifying pathway inside cells. When an extracellular ligand binds the receptor, it activates a heterotrimeric G-protein, which then stimulates adenylyl cyclase to produce the second messenger cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates many target proteins to produce the final cellular response.
How do I use the controls in this simulation?
Use the Ligand [L] slider to set the extracellular ligand concentration (range 10-12 to 10-4 M). The KD slider sets receptor binding affinity — lower KD means tighter binding. The Hill n slider controls cooperativity: values above 1 produce a steeper, more switch-like dose-response curve. The PDE activity slider adjusts how fast cAMP is degraded by phosphodiesterase, which limits peak cAMP and PKA levels. Use the preset buttons (Adrenaline, Insulin, Glucagon) to jump to physiologically realistic parameter sets.
What does signal amplification mean and how large is it in a GPCR cascade?
Signal amplification refers to the multiplicative increase in signalling molecules at each step of the cascade. A single activated receptor can stimulate hundreds of G-proteins; each G-protein activates an adenylyl cyclase that generates thousands of cAMP molecules per second; each cAMP can activate many PKA subunits. The total amplification factor from one ligand-binding event to final PKA activation can reach 10,000-fold or more, allowing cells to detect and respond to vanishingly small ligand concentrations.
What is the Hill equation and why does the Hill coefficient n matter?
The Hill equation describes how receptor occupancy (the fraction of receptors bound by ligand) depends on ligand concentration: occupancy = [L]n / (KDn + [L]n). When n = 1, the response rises gradually (hyperbolic); when n > 1, cooperativity sharpens the curve into a more switch-like (sigmoidal) transition that goes from near-zero to near-maximum response over a narrower concentration range. Many signalling cascades exploit high Hill coefficients to create digital, threshold-like decisions rather than gradual analog responses.
What are real-world examples of GPCR signalling in the body?
The beta-adrenergic receptor (beta-AR) pathway activated by adrenaline (epinephrine) is a classic example: it increases heart rate, dilates airways, and releases glucose during stress — all through cAMP/PKA. Glucagon signals low blood sugar to the liver via the same cAMP pathway, triggering glycogen breakdown. Retinal rod cells use a related cascade (rhodopsin/transducin/cGMP) for vision. Olfactory neurons use GPCRs to detect thousands of distinct odor molecules.
Is it true that more ligand always means more response?
Not exactly. The dose-response relationship is sigmoidal: at very low ligand concentrations the response is minimal; it rises steeply near the EC50 (approximately equal to KD for a simple Hill function with n = 1); and at high concentrations the response saturates at a maximum. Additionally, cells can adapt or desensitize — GPCRs become phosphorylated by GRKs (GPCR kinase) and internalized via beta-arrestin after prolonged stimulation, blunting the response even when ligand remains present.
Who discovered the cAMP second messenger system and when?
Earl Sutherland discovered cyclic AMP (cAMP) as a second messenger in 1957 while studying how adrenaline stimulates glycogen breakdown in liver cells. He showed that the hormone did not directly activate phosphorylase inside cells but triggered production of a heat-stable intermediate — cAMP — that did so. Sutherland was awarded the Nobel Prize in Physiology or Medicine in 1971. The G-protein component of the pathway was elucidated by Alfred Gilman and Martin Rodbell, who shared the 1994 Nobel Prize for this discovery.
What other signalling pathways are related to GPCR cascades?
GPCRs can couple to multiple G-protein subtypes: Gs stimulates adenylyl cyclase (this simulation), Gi inhibits it, and Gq activates phospholipase C to produce IP3 and DAG, mobilizing calcium and activating protein kinase C. Receptor tyrosine kinases (RTKs), such as the insulin receptor, use a parallel but distinct pathway through RAS and MAP kinase. Cross-talk between these pathways is common. The simulation also touches on Hill-function ultrasensitivity, which appears in many biological switches including the cell cycle and gene regulatory networks.
How is GPCR signalling used in drug development?
GPCRs are the most druggable target class in the human genome: approximately 35% of all FDA-approved drugs act by binding to GPCRs as agonists (mimicking the natural ligand), antagonists (blocking it), or allosteric modulators (altering receptor shape). Examples include beta-blockers (heart disease), antihistamines (allergies), opioids (pain), antipsychotics (dopamine receptors), and GLP-1 agonists (type 2 diabetes and obesity). Structural biology advances (X-ray crystallography and cryo-EM of GPCRs) have greatly accelerated rational drug design targeting these receptors.
What is PDE (phosphodiesterase) and why does its activity matter?
Phosphodiesterase (PDE) is the enzyme that degrades cAMP (and cGMP) back to inactive AMP, terminating the signal. High PDE activity means cAMP is rapidly cleared and PKA activation stays low even with strong receptor stimulation. Low PDE activity allows cAMP to accumulate to high levels. PDE inhibitors are clinically important drugs: caffeine weakly inhibits PDE (contributing to its stimulant effect), sildenafil (Viagra) inhibits PDE5 in smooth muscle, and theophylline inhibits PDE in lung tissue to treat asthma. In the simulation, reducing PDE activity dramatically amplifies the downstream PKA response.
What are current frontiers in cell signalling research?
Active research areas include biased agonism — where different drugs binding the same GPCR preferentially activate G-protein versus beta-arrestin pathways, enabling more selective therapies with fewer side effects. Single-cell imaging techniques now resolve cAMP and PKA activity in real time with nanometer precision using FRET biosensors. Computational systems biology models aim to capture the full complexity of signalling networks, including feedback loops, spatial gradients within cells, and crosstalk with hundreds of other pathways. Optogenetics uses light-activated GPCRs (opsins) to control signalling in specific neurons with millisecond precision.